However, systemic treatment against TNBC remains limited with the conventional chemotherapy as the mainstay, because patients with triple-negative disease do not benefit from endocrine therapy or anti-HER2-targeted therapy, which have been widely applied in the setting of ER/PR-positive or HER2-positive breast cancers with improved prognosis1–3. Here, ESR1 is linked to breast carcinoma.